Podcasts about clinical trials

Dr. Nikki Maphis didn't just lose a grant. She lost a lifeline. An early-career Alzheimer's researcher driven by her grandmother's diagnosis, Nikki poured years into her work—only to watch it vanish when the NIH's MOSAIC program got axed overnight. Her application wasn't rejected. It was deleted. No feedback. No score. Just gone.In this episode, Oliver Bogler pulls back the curtain on what happens when politics and science collide and promising scientists get crushed in the crossfire. Nikki shares how she's fighting to stay in the field, teaching the next generation, and rewriting her grant for a world where even the word “diversity” can get you blacklisted. The conversation is raw, human, and maddening—a reminder that the real “war on science” doesn't happen in labs. It happens in inboxes.RELATED LINKS:• Dr. Nikki Maphis LinkedIn page• Dr. Nikki Maphis' page at the University of New Mexico• Vanguard News Group coverage• Nature article• PNAS: Contribution of NIH funding to new drug approvals 2010–2016FEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Carla Tardiff has spent 17 years as the CEO of Family Reach, a nonprofit that shouldn't have to exist but absolutely does—because in America, cancer comes with a price tag your insurance doesn't cover.We talk about shame, fear, burnout, Wegmans, Syracuse, celebrity telethons, and the godforsaken reality of choosing between food and treatment. Carla's a lifer in this fight, holding the line between humanity and bureaucracy, between data and decency. She's also sharp as hell, deeply funny, and more purpose-driven than half of Congress on a good day.This episode is about the work no one wants to do, the stuff no one wants to say, and why staying angry might be the only way to stay sane.Come for the laughs. Stay for the rage. And find out why Family Reach is the only adult in the room.RELATED LINKSFamily ReachFinancial Resource CenterCarla on LinkedInMorgridge Foundation ProfileAuthority Magazine InterviewSyracuse University FeatureFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Jan Janisch-Hanzlik lives with MS and is a participant in one of the clinical trials evaluating the safety and efficacy of CAR-T cell therapy for MS. Jan is the first person in the world to receive this one-and-done treatment, and this week, she's joining me to share her experience participating in the clinical trial. But you'll be especially interested in hearing how CAR-T cell therapy has impacted Jan's MS. Open enrollment for people with Medicare and for those who get their health insurance through the ACA healthcare.gov Marketplace begins this week, and we're talking about some of the reasons you want to pay particular attention to your 2026 health insurance options. As the U.S. federal government shutdown enters its third week, we're reviewing some of the ways that the shutdown may affect someone living with MS. And we're giving you a reminder about how you can add your voice and share your story of living with MS with the FDA by participating in the Shaping Tomorrow Together initiative. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: A first-hand account of an important clinical trial, open enrollment begins, and how the government shutdown may affect people with MS  :22 Open enrollment for Medicare and Marketplace enrolees begins  :22 How the federal government shutdown could affect people living with MS  4:29 Your opportunity to tell the FDA what it's like to live with MS  8:57 Jan Janisch-Hanzlik shares her experience participating in a CAR-T cell therapy clinical trial, and how the treatment has impacted her MS  11:28 Share this episode  31:38 Next week's episode  31:57 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/424 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com PARTICIPATE: Take the Shaping Tomorrow Together Survey https://s.alchemer.com/s3/Perspectives-on-MS REGISTER: Attend the virtual Shaping Tomorrow Together meeting with the FDA https://nmss.quorum.us/event/25463 SIGN UP: Become an MS Activist https://nationalmssociety.org/advocacy JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms DOWNLOAD: The RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 DOWNLOAD: The RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 424 Guest: Jan Janisch-Hanzlik Privacy Policy

Examining the claim that cabbage family vegetables are bad for the thyroid; Walmart announces sweeping move to reformulate its products without synthetic dyes, sketchy additives; Under Congressional questioning, Google admits to censoring contrary narratives on YouTube during Covid; Children garner psychological benefits from grandparent time; J&J fined nearly $1 billion in landmark talc baby powder lawsuit; Humans are among the few animals who can't make their own vitamin C—why that may be a good thing.

Clinical trials pave the way for new breast cancer treatments, but many patients hesitate to take part. Dr. Elkhanany breaks down what these studies really mean and why access and education make a difference. What clinical trials are and how they work for patients Why every standard medicine starts with a trial How learning and access change treatment for everyone Key Questions Answered What is a clinical trial? Why do we need clinical trials? How do clinical trials progress from phase one to phase four? Why is it often difficult to get people to participate in clinical trials? How do you address patient skepticism towards clinical trials? Who decides if a new drug’s benefit is worth its risks? How do drug approval processes in the United States differ from those in Europe? What are the potential benefits for patients who participate in clinical trials? How do you approach a patient when recommending a clinical trial, especially if standard treatments have failed? What support systems exist to help patients participate in clinical trials, especially those traveling long distances or facing financial barriers? Timestamped Overview 00:00 Understanding Clinical Trials Stages 06:10 Advancing Medicine Through Clinical Trials 07:49 Cancer Treatment Decision Challenges 12:03 Global Drug Trial Decision Process 16:31 Immunotherapy Breakthrough in Cancer Treatment 20:10 Clinical Trials: Challenges and Importance 23:52 Key Patient Advice: Second Opinions 26:01 Bridging Clinical Trial Accessibility 29:05 Advancements Reducing Breast Cancer Mortality Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts.See omnystudio.com/listener for privacy information.

Clinical trials pave the way for new breast cancer treatments, but many patients hesitate to take part. Dr. Ahmed Elkhanany returns to the show to break down what these studies really mean and why access and education make a difference. What clinical trials are and how they work for patients Why every standard medicine starts with a trial How learning and access change treatment for everyone Key Questions Answered What is a clinical trial? Why do we need clinical trials? How do clinical trials progress from phase one to phase four? Why is it often difficult to get people to participate in clinical trials? How do you address patient skepticism towards clinical trials? Who decides if a new drug’s benefit is worth its risks? How do drug approval processes in the United States differ from those in Europe? What are the potential benefits for patients who participate in clinical trials? How do you approach a patient when recommending a clinical trial, especially if standard treatments have failed? What support systems exist to help patients participate in clinical trials, especially those traveling long distances or facing financial barriers? Timestamped Overview 00:00 Understanding Clinical Trials Stages 06:10 Advancing Medicine Through Clinical Trials 07:49 Cancer Treatment Decision Challenges 12:03 Global Drug Trial Decision Process 16:31 Immunotherapy Breakthrough in Cancer Treatment 20:10 Clinical Trials: Challenges and Importance 23:52 Key Patient Advice: Second Opinions 26:01 Bridging Clinical Trial Accessibility 29:05 Advancements Reducing Breast Cancer Mortality Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts.See omnystudio.com/listener for privacy information.

Dr. Geoff Dow, CEO of 60 Degrees Pharmaceuticals and former malaria drug developer at Walter Reed, joins the Tick Boot Camp Podcast to unpack the science and strategy behind treating babesiosis. Drawing parallels to malaria, Dow explains why tafenoquine (brand: Arakoda), FDA-approved for malaria prevention, is being studied for Babesia, how coinfections (Borrelia, Bartonella) complicate care, and why chronic illness needs a different clinical approach. He previews an upcoming Mount Sinai trial for chronic babesiosis focused on fatigue outcomes and discusses real-world diagnostics using FDA-approved blood donor screening plus PCRs from Galaxy Diagnostics and Mayo Clinic. The conversation also touches on prophylaxis concepts, immune dysregulation, and building a clearer path from anecdote to evidence for the tick-borne disease community. Guest Geoff Dow, BSc, MBA, PhD CEO & Board Member, 60 Degrees Pharmaceuticals Background: Biotechnology (Perth, Australia), PhD in malaria drug discovery, decade at Walter Reed Army Institute of Research, MBA in the U.S. Leads clinical programs exploring tafenoquine for babesiosis. Key Topics & Takeaways Malaria ↔ Babesiosis Parallels: Both are red-blood-cell parasites; acute symptoms driven by red cell destruction. Similar drug targets justify testing some anti-malarials against Babesia. Why Tafenoquine (Arakoda): An 8-aminoquinoline that induces oxidative stress in RBCs; distinct mechanism from atovaquone + azithromycin combo (current standard for acute babesiosis), potentially useful for resistance management. Chronic vs. Acute Disease: Acute babesiosis in immunocompetent patients often responds to standard care; chronic illness remains under-defined and underserved. Coinfections Are Common: Many chronically ill patients present with Borrelia, Bartonella, and Babesia together; diagnostics and treatment need to acknowledge polymicrobial reality. Upcoming Clinical Trial (Mount Sinai): Population: Chronic babesiosis with disabling fatigue, plus Babesia symptoms (e.g., air hunger, anemia) and lab evidence in the last 12 months. Regimen: 4-day loading dose then 200 mg weekly of tafenoquine for 3 months. Outcomes: Patient-reported fatigue (quality-of-life) + monthly molecular testing (FDA blood donor test, Galaxy Diagnostics PCR, Mayo Clinic PCR) during treatment and 3 months post-therapy. Goals: Demonstrate symptom improvement, assess eradication signals, and validate accessible diagnostics against an FDA-accepted assay. Prophylaxis & Post-Exposure Ideas: Animal data suggest short-course tafenoquine can eradicate early Babesia; human prophylaxis trials face feasibility and regulatory hurdles. Diagnostics Gap: Need for standardized, sensitive tools to define chronic babesiosis and track response. This trial also serves as a real-world diagnostic comparison. Immune Dysregulation & IACI: Overlap among long COVID, ME/CFS, post-treatment Lyme—shared theme of immune dysregulation with possible persistent antigen stimulation. Safety Notes: G6PD deficiency is relevant to 8-aminoquinolines; established safety database exists for malaria prevention dosing—critical as studies expand to babesiosis. Notable Quotes “You've got to put some lines in the sand—run the trial, collect data, and move the field forward.” “The best we can do for chronic disease starts with defining it—and validating the diagnostics we use to track it.” “8-aminoquinolines offer a different mechanism than current babesiosis standards—key for resistance and combinations.” Resources Mentioned Arakoda (tafenoquine): FDA-approved for malaria prevention; under study for babesiosis. Diagnostics: FDA-approved Babesia blood donor screen; Galaxy Diagnostics PCR; Mayo Clinic PCR. Organizations & Events: ILADS, Global Lyme Alliance, tick-borne disease conferences. Research Partners: Mount Sinai (NYC), Tulane University (Bartonella/Borrelia collaboration). Who Should Listen Patients with chronic Lyme or chronic babesiosis symptoms (fatigue, air hunger, anemia) Clinicians seeking updates on Babesia treatment research and diagnostics Caregivers and advocates tracking IACI and immune dysregulation science Researchers exploring antimalarial repurposing for tick-borne diseases Call to Action Subscribe to Tick Boot Camp and share this episode with someone navigating chronic tick-borne illness.

Welcome to a RealTalk MS special series on MS clinical trials. This special series is made possible through a generous grant from Sanofi.   In today's episode, we're exploring the risks and rewards of participating in a clinical trial with Dr. Kathy Zackowski and Mimi Brown.  Dr. Zackowski is the Associate Vice President of Research at the National MS Society, and she's going to offer an overview of the risks and benefits that you'll want to weigh in considering participating in a clinical trial. Mimi Brown lives with primary progressive MS, and Mimi is going to share her own experience as a participant in multiple clinical trials.    This special episode of RealTalk MS has been made possible through a generous grant from Sanofi. Sanofi has two ongoing Phase 3 clinical trials in MS studying Frexalimab, an investigational second-generation anti-CD40 ligand monoclonal antibody. If you are interested in learning more about these clinical trials, please visit SanofiStudies.com SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/ct2 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! Privacy Policy

CEO of Vistagen, Shawn Singh, returns to Inside Biotech to discuss groundbreaking developments in intranasal therapeutics. Shawn shares exciting results from Vistagen's fast-track phase 3 trials, explains how intranasal drug delivery bypasses limitations of traditional therapeutics relying on systemic absorption, and reflects on telehealth's role in accessibility. This conversation spotlights a transformative moment in neuroscience, drug development and mental health innovation.Learn more about Vistagen: https://www.vistagen.com/Listen to our previous episode with Shawn to learn more about social anxiety disorder and the earlier days of Vistagen: https://inside-biotech.simplecast.com/episodes/shawn-singh-ceo-of-vistagen-mental-health-biopharmaceuticals Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!To learn more about BCLA's events and consulting visit our website.Follow BCLA on LinkedIn

Send us a textDr. David Joseph rejoins Dr. Michael Koren for part 2 of his journey from reluctant med student to medical consultant, inventor, and artist. In this section, Dr. Joseph talks about the difficulties in navigating our current, disjointed, and often impersonal medical system. He recounts having to go through seven different consultations with physicians before anyone physically examined him and how persistence is key in our medical system. They finish up by talking about the doctor's artwork, which can be found at https://www.davidjosephart.com/ and on Instagram at @artbydavidjosephBe a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

In Part 2 of my interview with Lakshmi Grama, we find out what happened when the NCI team involved people affected by cancer in naming a new part of the cancer.gov website. Lakshmi also reveals how NCI was already exploring the possibilities of generative AI for precision communication about cancer. Missed Part 1 of our […] The post Lakshmi Grama on how people affected by cancer helped shape Cancer.gov’s Clinical Trials Information (Part 2) appeared first on Health Communication Partners.

On this episode of SurgOnc today, Dr. Rosalinda Alvarado and Dr. George Molina moderate a discussion on how to improve the recruitment of Hispanic/Latino patients into clinical trials. Joining the conversation are Jeanette Gonzalez from the University of Illinois Cancer Center and Alas-Wings, Dr. Narjust Florez from Dana-Farber Cancer Institute and Harvard Medical School, and Dr. Kennedy Timothy from MedStar Health and Georgetown University.

Kourosh Davarpanah, Co-Founder and CEO of Inato, is using an AI-enabled platform to transform participation in clinical trials. The existing clinical trial system is not seen as representative of the general population, and FDA directives have addressed this lack of diversity. The Inato platform features a marketplace approach that connects trial sponsors with a broader range of hospital sites, as well as an AI tool to assist doctors in identifying patients who are eligible for trials.   Kourosh explains, "Our focus at Inato is to expand the number of patients who are able to participate in clinical research. If you think about how things have been done for the past decades, most of the patients who have the opportunity to participate are coming from the larger academic hospitals. And what this means is that typically, 5% of the sites, meaning 5% of the hospitals running research, run about 70% of all the trials globally. So this has an impact not only on the number of patients that can actually participate in trials, but it also has an impact on the type of patients. So, typically, those are going to be white patients, richer patients. And so it has a big impact also on equity and on the diversity--and ethnic diversity especially--of patients participating."   "We have two pieces of the platform. The first piece is that we're helping connect the hospitals running the trials with trials that are being run by the sponsors. So the way this works is similar to marketplaces like Airbnb, where you have the sponsor that can share any number of upcoming trials. We enable the sites to discover all the trials on the platform and showcase, based on their profiles, how many trials they have done in the past, what is the makeup of the team and doctors, etc. We're able to allow them to get selected in trials that they otherwise wouldn't be able to get selected for. So this is the first piece of it, really connecting the sites and the trials. And increasingly with AI, we've started supporting sites in actually identifying patients at scale. And this has really been a massive tech shift, where the latest generations of LLMs are able to accurately identify patients eligible for any trial with over 95% accuracy." #Inato #ClinicalTrials #ClinicalRearch #AI #MedAI #DrugDevelopment  Inato.com Download the transcript here

Kourosh Davarpanah, Co-Founder and CEO of Inato, is using an AI-enabled platform to transform participation in clinical trials. The existing clinical trial system is not seen as representative of the general population, and FDA directives have addressed this lack of diversity. The Inato platform features a marketplace approach that connects trial sponsors with a broader range of hospital sites, as well as an AI tool to assist doctors in identifying patients who are eligible for trials.   Kourosh explains, "Our focus at Inato is to expand the number of patients who are able to participate in clinical research. If you think about how things have been done for the past decades, most of the patients who have the opportunity to participate are coming from the larger academic hospitals. And what this means is that typically, 5% of the sites, meaning 5% of the hospitals running research, run about 70% of all the trials globally. So this has an impact not only on the number of patients that can actually participate in trials, but it also has an impact on the type of patients. So, typically, those are going to be white patients, richer patients. And so it has a big impact also on equity and on the diversity--and ethnic diversity especially--of patients participating."   "We have two pieces of the platform. The first piece is that we're helping connect the hospitals running the trials with trials that are being run by the sponsors. So the way this works is similar to marketplaces like Airbnb, where you have the sponsor that can share any number of upcoming trials. We enable the sites to discover all the trials on the platform and showcase, based on their profiles, how many trials they have done in the past, what is the makeup of the team and doctors, etc. We're able to allow them to get selected in trials that they otherwise wouldn't be able to get selected for. So this is the first piece of it, really connecting the sites and the trials. And increasingly with AI, we've started supporting sites in actually identifying patients at scale. And this has really been a massive tech shift, where the latest generations of LLMs are able to accurately identify patients eligible for any trial with over 95% accuracy." #Inato #ClinicalTrials #ClinicalRearch #AI #MedAI #DrugDevelopment  Inato.com Listen to the podcast here

In this episode of Longevity by Design, our host, Dr. Gil Blander, sits down with Dylan Livingston, CEO at the Alliance for Longevity Initiatives, and Dr. Brenda Eap to explore how public policy shapes the future of aging research. Dylan and Brendan share how their team pushes for legislation that supports healthy lifespan extension, aiming to bring longevity science into the center of national health priorities.Dylan and Brendan explain why policy advocacy is crucial for securing funding for research, reducing regulatory hurdles, and establishing a clear path for new therapies. They outline recent successes, including building bipartisan support in Congress and expanding access to experimental treatments in states such as Montana. Throughout their discussion, Dylan shows how effective communication,  using stories and simple analogies, helps move longevity from the lab to lawmakers' agendas.The episode closes with practical advice for listeners. Dylan highlights the power of community, clear communication, and grassroots action as tools that help turn advanced science into real-world health gains.Episode highlights:[00:00:00]: Introduction[00:01:00]: Overview of Longevity Policy and Research Funding[00:02:00]: Backgrounds and Personal Journeys into Longevity Advocacy[00:05:00]: Inspiration and Founding of Longevity Policy Organization[00:07:00]: Scientific Training and Motivation for Policy Work[00:09:00]: Mission and Approach of Longevity Advocacy Organization[00:10:00]: Policy Advocacy's Role in Advancing Longevity Research[00:12:00]: Gaps in Funding and the Importance of Government Engagement[00:13:00]: Experiences with Policy Events and Realizations about Advocacy[00:14:00]: Early Accomplishments and Congressional Engagement[00:15:00]: Building Bipartisan Support and the Longevity Science Caucus[00:16:00]: Legislative Engagement and Policy Paper Development[00:17:00]: State-Level Policy Wins and Expansion of Right to Try Laws[00:19:00]: Rationale and Strategy for State-Level Focus[00:21:00]: Plans for Geographic Expansion of Longevity Policy Initiatives[00:23:00]: Political Climate and Opportunities with the Current Administration[00:25:00]: Shifts in Federal Attitudes Toward Longevity and Healthspan[00:27:00]: Demographics, Policy Momentum, and National Health Priorities[00:29:00]: Prevention Versus Treatment: Shifting Policy Mindsets[00:32:00]: Communicating Policy Opportunities to a Wider Audience[00:34:00]: Ensuring Longevity Policy Remains Bipartisan[00:35:00]: Intersection of Policy, Science, and Public Engagement[00:37:00]: Funding and Regulatory Challenges in Longevity Research[00:39:00]: Barriers in Clinical Trials and Policy Modernization[00:40:00]: Strategies for Communicating Longevity Science to Policymakers[00:44:00]: Framing Longevity for Policy Impact and Public Understanding[00:48:00]: Future Vision and Milestones for Longevity Policy[00:51:00]: How Individuals and Organizations Can Support Longevity Advocacy[00:55:00]: Practical Longevity Advice and Episode ConclusionWe Appreciate You!As a token of our gratitude, we're excited to offer you 15% off your next purchase. Simply click the link below to redeem your discount: https://info.insidetracker.com/podcastFor science-backed ways to live a healthier, longer life, download InsideTracker's Top 5 biomarkers for longevity eBook at insidetracker.com/podcast

If you've ever felt alone in the healthcare maze, this episode is here to remind you: your story matters, and you are not alone. Kavita Bouknight shares how her personal health journey and family experiences inspired her mission to make healthcare information more accessible, and how she's leveraging technology through her company's program, SPARK, to bridge crucial communication gaps between patients and providers. The conversation explores the needs and future of women's health, the entrepreneurial path, and the importance of advocating for yourself and others in today's complex medical landscape.    TIMESTAMPS: 00:00 "Match Health Collective Founder Interview" 03:40 "Navigating Care in Sandwich Generation" 08:01 Navigating Stressful Situations 10:10 Navigating Healthcare Isolation 16:01 Patient Engagement in Clinical Trials 19:48 Advocating for Clear Breast Health 22:17 Dense Breast Tissue Awareness 25:49 Take the Leap and Evolve 27:18 Entrepreneurial Evolution and Vision 29:51 Naming Expertise Transforms Business 34:06 Boosting Women's Health Awareness 38:21 Feeling Alone Despite Support 39:39 Expressing Gratitude and Support   LEARN MORE: The Clear Pathways Program: https://www.breastdensitysummit.org/ MAKE A DONATION: https://www.paypal.com/donate?hosted_button_id=NJMF86A8Y9RJQ Women's Health Advocates: https://womenshealthadvocates.org/   With a focus on health innovation and high-impact marketing, Kavita Bouknight is a trusted advisor to venture-backed startups and publicly traded healthcare organizations, bringing over 20 years of experience in strategy and go-to-market execution. She is the Founder and CEO of Match Health Collective, a full-service marketing agency that helps medical device and life science companies build brands, accelerate clinical adoption, and engage patients and physicians. She also leads Match Health Academy, which develops programs and tools to drive meaningful engagement and make complex health information more accessible through video and text-based communication. FOLLOW KAVITA:  Website: https://matchhealth.com Kavita LinkedIn: https://linkedin.com/in/kavitabouknight/ Match Health Collective LinkedIn: https://www.linkedin.com/company/match-health-collective/?viewAsMember=true   FOLLOW LISA: https://www.linkedin.com/in/lisamalianorman/ https://www.instagram.com/lisamalia.evoke/  

Send us a textDr. David Joseph joins Dr. Michael Koren in part 1 of this 2-part series to discuss his journey into the medical world - with myriad tangents and diversions along the way. Dr. Joseph explores his journey from scrappy teen entrepreneur and freshman MIT researcher and inventor to Harvard-trained anesthesiologist. He talks about his non-standard approach to applying to and studying at Harvard Medical School and how his nontraditional approach to life has led him to interesting places.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Jennifer J. Brown is a scientist, a writer, and a mother who never got the luxury of separating those roles. Her memoir When the Baby Is Not OK: Hopes & Genes is a punch to the gut of polite society and a medical system that expects parents to smile through trauma. She wrote it because she had to. Because the people who gave her the diagnosis didn't give her the truth. Because a Harvard-educated geneticist with two daughters born with PKU still couldn't get a straight answer from the very system she trained in.We sat down in the studio to talk about the unbearable loneliness of rare disease parenting, the disconnect between medical knowledge and human connection, and what it means to weaponize science against silence. She talks about bias in the NICU, the failure of healthcare communication, and why “resilience” is a lazy word. Her daughters are grown now. One's a playwright. One's an artist. And Jennifer is still raising hell.This is a conversation about control, trauma, survival, and rewriting the script when the world hands you someone else's lines.Bring tissues. Then bring receipts.RELATED LINKS• When the Baby Is Not OK (Book)• Jennifer's Website• Jennifer on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Clinical trials are essential for improving the lives of those diagnosed with Alzheimer's disease and related dementias. With so many trials out there, it can be difficult for someone who's interested in participating in research to know where to start. Dr. Jonathan Graff-Radford joins the podcast to discuss the ins and outs of clinical trials and the state of Alzheimer's treatments today, as well as share some highlights from his presentation at the National Alzheimer's Coordinating Center's (NACC) 2025 Spring ADRC Meeting. Guest: Jonathan Graff-Radford, MD, behavioral neurologist, associate professor, vice chair, Mayo Clinic Department of Neurology, co-investigator, Mayo Clinic Alzheimer's Disease Research Center Show Notes Read more about Dr. Jonathan Graff-Radford at his profile on Mayo Clinic's website. Listen to part one and part two of our series on preclinical Alzheimer's disease and the AHEAD study with Dr. Reisa Sperling, mentioned at 19:53, on our website. Learn more about the AHEAD study on their website. Learn more about clinical trials in Wisconsin at the UW Clinical Trials Institute's website. Interested in participating in clinical trials? Visit clinicaltrials.gov or Alzheimer's Association's TrialMatch to learn how to get involved. Learn more and register for the 2025 Fall Community Conversation: Addressing Hearing Loss for Better Brain Health on our website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter. Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer's. All donations go toward outreach and production.

It's not always easy to participate in a clinical trial.  Even if you want to, how do you get the time off from work?  Starting in 2025, thanks to the Foundation for Sarcoidosis Research, there is a provision called the FMLA Clarification, which essentially states that you can participate without fear of losing your job.  In this episode of the FSR Sarc Fighter Podcast, Dr. Ennis James, a sarcoidosis researcher and physician at the Medical University of South Carolina, and Tricha Shivas, Chief of Staff and Strategy at FSR join me to talk about how difficult life can be for patients.  Dr. James shares a real-life story about a woman who fought to stay in a trial after problems arose at work.   SHOW NOTES OP-ED by Dr. Ennis James in STAT: https://www.statnews.com/2025/09/24/clinical-trial-patient-fmla-foundation-sarcoidosis-research-job-security/ SHRM: https://www.shrm.org/ FSR News Release: https://www.stopsarcoidosis.org/coalition-to-transform-clinical-trial-engagement-launches-champions-for-change-pto-initiative/ More from FSR: https://www.stopsarcoidosis.org/fsr-receives-confirmation-from-the-department-of-labor-ensuring-patient-access-to-fmla-for-participation-in-clinical-trials/ MORE FROM JOHN: Cycling with Sarcoidosis http://carlinthecyclist.com/category/cycling-with-sarcoidosis/ Do you like the official song for the Sarc Fighter podcast?  It's also an FSR fundraiser! If you would like to donate in honor of Mark Steier and the song, Zombie, Here is a link to his KISS account.  (Kick In to Stop Sarcoidosis)  100-percent of the money goes to the Foundation.  https://stopsarcoidosis.rallybound.org/MarkSteier The Foundation for Sarcoidosis Research https://www.stopsarcoidosis.org/ Donate to my KISS (Kick In to Stop Sarcoidosis) fund for FSR  https://stopsarcoidosis.rallybound.org/JohnCarlinVsSarcoidosis?fbclid=IwAR1g2ap1i1NCp6bQOYEFwOELdNEeclFmmLLcQQOQX_Awub1oe9bcEjK9P1E My story on Television https://www.stopsarcoidosis.org/news-anchor-sarcoidosis/ email me  carlinagency@gmail.com #sarcoidosis #sarcoidosisawareness #fmla #fmlaclarification                    

In this compelling episode of the Eye Believe Podcast

Send us a textDr. Michael Koren joins Kevin Geddings to discuss the positive headline results from a clinical study on the cholesterol medication Repatha. Dr. Koren explains what "headline results" are and how they differ from results presented in a full scientific format. He talks about how these findings are being released due to market regulations to keep the parent company of Repatha, Amgen, from violating financial laws. Dr. Koren also explains that these results are encouraging for people with high cholesterol. The study was using Repatha as a potential preventative medication and preliminary results are looking good!Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

With Allan Sniderman, McGill University, Montreal - Canada.  Link to European Heart Journal Editorial, by Allan Sniderman, Michael J. Pencina and George Thanassoulis Link to European Heart Journal Paper

This episode of Standard Deviation features Oliver Bogler in conversation with Dr Na Zhao, a cancer biologist caught in the crossfire of science, politics, and survival. Na's life reads like a brutal lab experiment in persistence.She grew up in China, lost her mother and aunt to breast cancer before she turned twelve, then came to the United States to chase science as both an immigrant and a survivor's daughter. She worked two decades to reach the brink of independence as a cancer researcher, only to watch offers and grants vanish in the political chaos of 2025.Oliver brings her story into sharp focus, tracing the impossible climb toward a tenure-track position and the human cost of a system that pulls the ladder up just as people like Na reach for it. This conversation pulls back the curtain on the NIH funding crisis, the toll on early-career scientists, and what happens when personal tragedy fuels professional ambition.Listeners will walk away with a raw sense of how fragile the future of cancer research really is, and why people like Na refuse to stop climbing.RELATED LINKSDr Zhao at Baylor College of MedicineDr Zhao on LinkedInDr Zhao's Science articleIndirect Costs explained by US CongressFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The emerging therapy improved vision for some participants in an earlier clinical trial.

In this episode of the Intelligent Medicine podcast, Dr. Ronald Hoffman delves into the critical role of mitochondria in overall health with a particular emphasis on skincare with Dr. Julie Faitg, a mitochondrial biologist and senior manager of Applied Research and Regulatory Affairs at Timeline. The discussion highlights the broad impacts of mitochondrial health on lifestyle, diet, sleep, exercise, and psychological well-being. Focusing specifically on Urolithin A (MitoPure), they explore its promising benefits for muscle strength, endurance, and skin health through cellular renewal processes like mitophagy. Dr. Faitg emphasizes the clean formulation and clinical effectiveness of Timeline's various supplements and skincare products, underscoring their role in extending healthspan and rejuvenating skin from the outside in. The episode provides practical insights on product usage and the broader implications of mitochondrial science for anti-aging and wellness.

Dr. Hoffman continues his conversation with Dr. Julie Faitg, a mitochondrial biologist and senior manager of Applied Research and Regulatory Affairs at Timeline. 

Send us a textChristy Kestner, PhD, joins Erich Schramm, MD to discuss her journey from bench scientist to medical communicator. She talks about the importantce of spreading knowledge far and wide, particularly in the current era of massive misinformation. The duo talk about the problem of keeping medical and scientific information in silos and how communicators like Christy Kestner can help other scientists and doctors communicate more effectively with the public and patients alike. Christy Kestner introduces her work at Endosymbiont and her platform at Brain and Beyond to help people understand the complex world of medicine. Dr. Schramm then asks about some of the upcoming neuroscience research, including with brain computer interfaces, ALS, and Alzheimer's treatments.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Katie Henry has seen some things. From nonprofit bootstraps to Big Pharma boardrooms, she's been inside the machine—and still believes we can fix it. We go deep on her winding road from folding sweaters at J.Crew to launching a vibrator-based advocacy campaign that accidentally changed the sexual health narrative in breast cancer.Katie doesn't pull punches. She's a born problem solver with zero tolerance for pink fluff and performative empathy. We talk survivor semantics, band camp trauma, nonprofit burnout, and why “Didi” is the grandparent alter ego you never saw coming.She's Murphy Brown with a marimba. Veronica Sawyer in pharma. Carla Tortelli with an oncology Rolodex. And she still calls herself a learner.This is one of the most honest, hilarious, and refreshingly real conversations I've had. Period.RELATED LINKS:Katie Henry on LinkedInKatie Henry on ResearchGateLiving Beyond Breast CancerNational Breast Cancer CoalitionFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Hoffman continues his conversation with Nicole Bell, the CEO of Galaxy Diagnostics and author of “What Lurks in the Woods.” 

This episode of the Intelligent Medicine podcast is a deep dive into the complexities of Lyme disease and other tick-borne illnesses. Nicole Bell, the CEO of Galaxy Diagnostics and author of “What Lurks in the Woods,” details the challenges of diagnosing tick-borne diseases, the limitations of current diagnostic tests, and the controversy around treatment methodologies. Nicole shares her personal journey that led her to this field after her husband was misdiagnosed with early-onset Alzheimer's, which was later revealed to be caused by advanced Lyme disease. They also discuss new diagnostic techniques, the importance of personalized treatment plans, and ongoing advocacy efforts to improve awareness and research funding for Lyme disease.

Durable vision improvements were also observed out to 18 months for previously dosed adult patients in the trial.

In this episode of the ThinkData Podcast, I sit down with Ro Wickramasinghe, Global Head of Business Development at Pi Health, the AI platform rethinking how clinical trials are run.We explore:

Send us a textDr. Michael Koren joins Kevin Geddings in talking about the start of flu season and the benefits of getting a flu shot through the clinical trials process. The doctor explains that modern flu shot trials don't use a placebo, they compare two different types of flu shot but everyone is protected. The two also discuss some of the rumors and mysteries surrounding flu shots, including why patients 65 and up sometimes get offered a different vaccine than those younger.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

With David Erlinge and Sasha Koul, Lund University, Lund - Sweden Read the European Heart Journal paper Read the European Heart Journal editorial

Send us a textWhat if you could hold in your hands a roadmap to the most influential studies that have shaped modern neonatology? In this special episode of The Incubator Podcast, Ben and Daphna sit down with Dr. John Zupancic, Dr. Susanna Hay, and Dr. Roger Soll to discuss the release of their new book, 50 Studies Every Neonatologist Should Know. Together with their co-editors Dr. Barbara Schmidt and Dr. Haresh Kirpalani, the team has distilled decades of neonatal research into an accessible, thoughtfully structured volume designed to guide clinicians, trainees, and educators.The conversation explores the motivation behind the book, the editorial process of selecting just 50 landmark trials from thousands, and the importance of revisiting historical studies to understand how evidence has evolved over time. From the groundbreaking DART trial to the early work of pioneers like Bill Silverman, the authors emphasize not only the science but also the stories, challenges, and human insights that lie behind each study.Whether you are a seasoned neonatologist or just beginning your training, this episode provides a behind-the-scenes look at a project that brings clarity and context to evidence-based practice.

Osteosarcoma Webinar Series: Amy Armstrong, MD, a pediatric oncologist at Siteman Kids, joins us on OsteoBites to discuss an open-label, cohort-sequential dose-escalation and dose-confirmation Phase 1/2 clinical trial to evaluate the safety and efficacy of domatinostat in combination with sirolimus in adolescents and adults with relapsed, refractory sarcoma and osteosarcoma. She will review background, patient selection, treatment plan and study calendar for this clinical trial.Dr. Amy Armstrong is a pediatric oncologist who directs the Solid Tumor Program at Siteman Kids, affiliated with St. Louis Children's Hospital, as well as co-directs the Adolescent and Young Adult Sarcoma Program in collaboration with Siteman Kids and Siteman Cancer Center. She is an Associate Professor of Pediatrics at Washington University in St. Louis and has research interests in Neurofibromatosis Type 1-related plexiform neurofibromas, renal tumors, and sarcomas found most commonly in the adolescent and young adult population. Dr. Armstrong serves as site Principal Investigator for the Children's Oncology Group, Neurofibromatosis Clinical Trials Consortium and National Pediatric Cancer Foundation and is invested in conducting and developing clinical trials to serve a diverse range of solid tumors in both the upfront and relapsed setting.

Today I get to talk with Lakshmi Grama, former Associate Director for Dissemination and Digital Communications at the National Cancer Institute. She shares stories of early days at NCI, bringing everyone to the table, and power dynamics in health information. Communication about clinical trials is a very specialized part of health communication, but stories from […] The post Lakshmi Grama on how people affected by cancer helped shape Cancer.gov's Clinical Trials Information (Part 1) appeared first on Health Communication Partners.

In this episode, we take a deep dive into the state of the treatment pipeline for bleeding disorders. From the way clinical trials are structured to what's actually available for different conditions, we examine both the promise and the reality of innovation in this space. Recorded live at the NBDF Bleeding Disorders Conference, we join Mike Recht, MD, PhD, Chief Science and Medical Officer of NBDF, for a “research posters walk & talk” to explore what's happening right now — and why so many promising treatments never make it to market. Guests: Mike Recht, MD, PhD Maria Santaella, PhD(c), MSN, RN-BC, CPHON Samantha Carlson, LMSW   Senior Advisor: Donna DiMichele, MD   Hosted by: Patrick James Lynch   Written by: Kay Vermeil   Featured Advertiser: Sanofi   Subscribe to the Global Hemophilia Report   Show Notes:   Join Kevin as he shares about his journey with hemophilia and the hurdles he faced in communicating with friends, family, and healthcare providers about his condition. He highlights how hemophilia affects far more than just physical health — and why honest, open conversations that focus on the full patient experience, not just symptoms, are so essential.   Click here to watch his story: https://www.youtube.com/watch?v=3v1cCTbhClA&list=PLmqBxf22n4lNK82h3QZ-9YlpIjYdzDOer&index=5   Sanofi's Global Hemophilia Survey uncovers significant care gaps and emotional challenges faced by patients and caregivers. Learn how improving health literacy and fostering better patient-provider communication are essential to addressing these inequities. Explore the findings and see how Sanofi is driving health equity for the hemophilia community. Explore the survey findings here: Global Hemophilia Survey Page. Connect with the Global Hemophilia Report Global Hemophilia Report on LinkedIn Global Hemophilia Report on X/Twitter Global Hemophilia Report on Facebook   Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on X/Twitter   

Welcome to The Peptide Podcast. In this episode, we're unpacking the latest on retatrutide and how it measures up against semaglutide and tirzepatide.  If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  https://pepties.com/partners/ We'll look closely at what the studies tell us so far — from overall weight loss to reductions in visceral fat and how much lean muscle mass is preserved. We'll also talk about where the evidence is solid, where it's still developing, and why cross-trial comparisons should be made with caution. What is retatrutide? So let's start with the basics—what is retatrutide? Retatrutide is a new type of weight-loss medication called a triple agonist. That sounds fancy, but what it really means is that it targets three hormone receptors in the gut and pancreas: GLP-1, GIP, and glucagon. Each of these plays a slightly different role in metabolism and appetite regulation. To break it down: GLP-1, which you might already know from drugs like semaglutide, mainly slows digestion, helps you feel full, and improves insulin sensitivity. GIP, which tirzepatide targets along with GLP-1, also helps regulate blood sugar and may improve how the body stores and burns fat. Retatrutide adds glucagon receptor activation on top of that, which seems to further boost fat burning. So how does this compare to semaglutide and tirzepatide? Semaglutide is a GLP-1-only drug, so it mainly works by reducing appetite and slowing gastric emptying. Tirzepatide is a dual agonist, hitting GLP-1 and GIP, which gives it a slightly stronger effect on blood sugar control and fat metabolism compared to semaglutide. Retatrutide goes one step further by adding glucagon activity, potentially giving more total fat loss. In other words, you can think of it like a spectrum: semaglutide hits one target, tirzepatide hits two, and retatrutide hits three—each additional receptor seems to enhance metabolic effects and fat loss in clinical trials. That's why people are excited about retatrutide, though it's still early, and we're waiting on larger studies to see exactly how it compares head-to-head with the others. And that's going to be key, since right now we don't have direct comparisons to other advanced therapies like semaglutide or tirzepatide in the published Phase 2 data. How does retatrutide compare to semaglutide and tirzepatide? Total body weight loss: Now let's put these three medications side by side and look at what the trials actually tell us about total body weight loss. Starting with retatrutide: in its Phase 2 obesity program, the numbers were unusually large, especially given the relatively short trial window. In the 48-week study, people on the higher doses—8 or 12 milligrams weekly—lost about 22 to 24% of their body weight on average. That's the result that really made headlines. It's worth noting that some trials report slightly different averages depending on the group studied—people with obesity but no diabetes versus people with type 2 diabetes—but across the board, that 48-week signal is consistently very strong. For comparison, let's step back to semaglutide at the 2.4 mg dose, which was tested in the pivotal STEP-1 trial. Over 68 weeks, participants lost about 15% of their body weight on average. That was a landmark finding when it was published in the New England Journal of Medicine—it essentially set the modern benchmark for what a GLP-1 monotherapy could do. Then we have tirzepatide, the dual GIP and GLP-1 agonist. The SURMOUNT-1 trial, which ran for 72 weeks, showed dose-dependent results: about 15% weight loss at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, compared to only around 3% with placebo. Other obesity studies with tirzepatide have backed this up, especially at the higher doses. And in head-to-head comparisons with semaglutide, tirzepatide has consistently come out on top. So if we zoom out: retatrutide's Phase 2 data suggest the greatest average reductions—over 22%—in less than a year. Tirzepatide follows closely behind with around 21% over 72 weeks. And semaglutide shows very meaningful, but smaller, weight loss of around 15% over a similar time frame. The big caveat here is that these aren't perfect apples-to-apples comparisons. The trials differed in their length, the types of patients enrolled—some had type 2 diabetes, some did not—their baseline weights, and even the way results were reported. Plus, retatrutide is still in Phase 2 for obesity, whereas semaglutide and tirzepatide already have large Phase 3 programs and real-world data backing them up. Visceral fat reduction: Next, let's talk about visceral fat reduction—that's the deep fat that surrounds organs like the liver, pancreas, and intestines. It's particularly important because high levels of visceral fat are strongly linked to cardiometabolic disease. Starting with retatrutide, one of the Phase 2 substudies used DEXA scans to measure body composition in detail. At the higher doses—8 and 12 milligrams per week—participants saw visceral fat drop by about 29 to 31% over 48 weeks. That's a very large relative reduction in under a year and one of the reasons people are excited about retatrutide's potential not just for weight loss, but also for improving long-term metabolic health. How does that compare to the other drugs? With semaglutide, we also have DEXA and imaging substudies from the STEP program and follow-up mechanistic work. These consistently show meaningful visceral fat reductions, along with improvements in the ratio of lean to fat mass. The difference is that semaglutide studies typically report VAT changes as “significant and clinically relevant,” but they don't always publish one clear headline number that's directly comparable to retatrutide's ~30%. In other words, semaglutide definitely lowers visceral fat, but depending on the study and population, the exact percentage looks different. For tirzepatide, we also have imaging-based data from the SURMOUNT trials and related body-composition studies. These show that the majority of weight lost is fat mass—including a significant portion of visceral fat. Some analyses report reductions on par with what's seen with GLP-1 therapies, while others suggest tirzepatide may push a bit further. But again, the actual percentages vary depending on whether the study used DEXA, CT, or MRI, and on who was enrolled. The big caveat here is that we don't yet have a head-to-head imaging study comparing all three drugs in the same population with the same methods. Retatrutide's ~30% visceral fat drop is certainly eye-catching, but without that kind of standardized comparison, it's hard to say definitively whether it's truly better than semaglutide or tirzepatide. Lean muscle mass preservation: Now let's shift to lean mass preservation, which is just as important as total weight or fat loss. Across all of the modern obesity drug trials, one thing has been consistent: most of the weight people lose is fat, but some lean tissue is lost too. That's expected whenever you're in a sustained calorie deficit. The question is how much muscle is preserved, and how the proportions break down. With retatrutide, the DEXA substudy showed something reassuring. Even though people lost a lot of total weight and fat, the proportion of lean mass lost compared to total weight loss was similar to what we see with other therapies. In other words, the drug seems to drive large fat reductions without causing disproportionate muscle loss. Interestingly, the absolute amount of lean tissue lost in kilograms was pretty stable across different doses, even though fat loss varied quite a bit. That suggests the extra weight loss with higher doses is really coming from fat, not muscle. Looking at semaglutide, the STEP trials with DEXA scans reported the same general pattern. People lost more fat than lean mass, and when you adjust for the total weight loss, body composition actually improved. In fact, some analyses showed a slight increase in the percentage of body weight that was lean tissue, even though the absolute lean mass in kilograms went down. So again, it's not that muscle isn't affected—it is—but fat loss makes up the majority of the change. For tirzepatide, the SURMOUNT body-composition studies found that about 75% of the weight lost is fat and about 25% is lean mass. That split is very similar to what was seen in the placebo groups, which means the drug isn't shifting the balance unfavorably. It preferentially reduces fat, while lean mass preservation is in the same ballpark as semaglutide and retatrutide. Now, here's the important nuance: lean mass on a DEXA scan isn't just skeletal muscle. It includes water, organ tissue, and other components. So if someone loses 3 or 4 kilograms of “lean mass,” we don't know how much of that is functional muscle versus water or smaller organ size. That's why these numbers can be misleading if you take them at face value. And this is where lifestyle comes in. Resistance training and adequate protein intake are critical alongside medication. Lifting weights or doing bodyweight resistance work helps preserve functional muscle, while getting enough protein—typically somewhere in the range of 0.8 to 1 gram per pound per day depending on age and activity—supports muscle repair and maintenance. Every trial we've seen shows that the best outcomes, in terms of maintaining strength and function, come from pairing these drugs with exercise and nutrition strategies. That way, the unavoidable lean mass changes have far less impact on long-term metabolic health and performance. Limitations, biases, and what's missing (the critical context). No large, peer-reviewed head-to-head trials (yet) comparing retatrutide with semaglutide or tirzepatide for the same endpoints using identical imaging protocols. Most comparisons are cross-trial and therefore imperfect. Retatrutide Phase-2 was often compared to placebo or dulaglutide (in the T2D DEXA substudy) rather than to semaglutide or tirzepatide. A head-to-head (planned/registered) study vs tirzepatide is listed on ClinicalTrials.gov but results are not published yet. Different populations & durations. Some retatrutide data come from cohorts that include people with T2D or NAFLD; semaglutide STEP trials were often in people with obesity (without diabetes) and run longer (68 weeks), while tirzepatide SURMOUNT trials ran to 72 weeks. These differences change the absolute and percent outcomes. Funding and reporting bias. Many of the early retatrutide analyses are industry-funded (Eli Lilly), which is standard for drug development, but it requires us to carefully read methods, endpoints, and completeness of reporting. Independent replication and Phase-3 confirmation matter. Imaging method variation. VAT reported by DXA vs MRI vs CT are not directly interchangeable. Some trials report VAT area, others percent change; that complicates cross-trial percent comparisons.  Thanks for listening to The Peptide Podcast. If today's episode resonated, share it with a friend. Until next time, be well, and as always, have a happy, healthy week.

Send us a textTriple-board certified psychologist Dr. Heather Luing joins Dr. Erich Schramm to talk about depression. Major depressive disorder affects one in five Americans and ranks among the most disabling conditions worldwide. In spite of this, treatments for depression can be unsatisfying or ineffective for up to 1/3 of patients. The doctors discuss the symptoms, treatments, and biological underpinnings of depression. They move to advances in medications and devices and the possibilities that clinical trials hold for the not-too-distant future, including non-medical solutions like Transcranial Magnetic Stimulation and Vagus Nerve Stimulation for medication-resistant patients.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

How can we fix a healthcare system that has too often overlooked women? In this episode, host Elaine Hamm, PhD, speaks with Georgie Kovacs, MBA, Founder and CEO of Fempower Health, about her mission to empower women through evidence-based information and community support. Georgie shares her journey from personal experience with endometriosis to building a trusted platform that connects women with leading experts. Together, Elaine and Georgie dig into the history—and ongoing challenges—of women's inclusion in clinical trials, the gaps in data that still shape care today, and why patient advocacy and systemic change are more critical than ever. In this episode, you'll learn: Why women were historically excluded from clinical trials—and the consequences still felt today. How patient advocacy, informed consent, and inclusion can reshape women's healthcare. What biotech leaders, clinicians, and investors must consider when designing studies and funding women's health innovations. Tune in to hear Georgie's vision for transforming women's health from fragmented care into informed, empowered, and equitable solutions. Links: Connect with Georgie Kovacs, MBA, and check out Fempower Health. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Check out the Endometriosis Working Group and take the survey. Learn more about the Tulane Center of Excellence in Sex-Based Precision Medicine. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

FDA announces crackdown on misleading TV drug ads, influencers, online drug dispensaries; What's a “twisted colon”? Doctors often jump the gun in prescribing ADHD meds to young kids before behavioral fixes; A new era in skincare powered by urolithin A.

Let's say you or a family member wants to participate in a clinical trial, but the boss doesn't want you to have the time off because of extra visits to the doctor's office. Under new rules spearheaded by the Foundation for Sarcoidosis Research, companies must now allow patients time away from the job without fear of losing their employment.  In this special edition of the FSR Sarc Fighter Podcast, FSR CEO Mary McGowan joins me, along with Emily Dickens, Chief of Staff, Head of Government Affairs, and Corporate Secretary for Society for Human Resources Management.  Together they will walk us through the new guidelines for HR departments when it comes to allowing employees to participate in clinical trials.  @SHRM #SHRM #humanresources #clinicaltrial  Show Notes SHRM: https://www.shrm.org/ FSR News Release: https://www.stopsarcoidosis.org/coalition-to-transform-clinical-trial-engagement-launches-champions-for-change-pto-initiative/ More from FSR: https://www.stopsarcoidosis.org/fsr-receives-confirmation-from-the-department-of-labor-ensuring-patient-access-to-fmla-for-participation-in-clinical-trials/ MORE FROM JOHN: Cycling with Sarcoidosis http://carlinthecyclist.com/category/cycling-with-sarcoidosis/ Do you like the official song for the Sarc Fighter podcast?  It's also an FSR fundraiser! If you would like to donate in honor of Mark Steier and the song, Zombie, Here is a link to his KISS account.  (Kick In to Stop Sarcoidosis)  100-percent of the money goes to the Foundation.  https://stopsarcoidosis.rallybound.org/MarkSteier The Foundation for Sarcoidosis Research https://www.stopsarcoidosis.org/ Donate to my KISS (Kick In to Stop Sarcoidosis) fund for FSR  https://stopsarcoidosis.rallybound.org/JohnCarlinVsSarcoidosis?fbclid=IwAR1g2ap1i1NCp6bQOYEFwOELdNEeclFmmLLcQQOQX_Awub1oe9bcEjK9P1E My story on Television https://www.stopsarcoidosis.org/news-anchor-sarcoidosis/ email me  carlinagency@gmail.com #sarcoidosis #sarcoidosisawareness               

On this month's Time for a Check Up Sean Sullivan talked to Southern Cancer Center's Karla Childers about Clinical Trials.  Clinical trial are important to test medications that can help in the future!  How does it work??  Listen here:

Send us a textDr. Michael Koren joins Kevin Geddings to discuss the pivotal role imaging has played in diagnosis and understanding of various diseases. Dr. Koren notes that before the science of imaging, the only way to see what was going on inside the body was with a knife. They then discuss some of the newest applications of imaging and how the use of CT scans and amyloid PET scans can see inside the heart and arteries to see how a disease is progressing or the effectiveness of new medications.They talk about the progress that has been made and how we are able to see what's happening, but note that access to these imaging technologies is not evenly available and that sometimes cost or insurance can get in the way of healthcare access. Dr. Koren then points out that clinical research may offer some patients a way for some patients to access these imaging technologies outside of the traditional healthcare system if they have risks or signs of diseases being studied.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

EP. 231:  On this episode we're digging into one of the most exciting frontiers in cellular medicine: how Urolithin A, a powerful compound, supports mitochondrial health and slows the effects of aging at the cellular level. If you've been feeling low energy, dealing with inflammation, or noticing your strength and resilience aren't what they used to be, this episode is packed with science-backed insights to help recharge your body from the inside out. My guest today is Dr. Brad Currier, PhD, Manager of Clinical Trials at Timeline, who's leading the way in Urolithin A research. We're talking muscle metabolism, brain health, immunity, and how this prebiotic compound could be a total game changer for longevity and overall vitality. → Head to timeline.com/DRTYNA to get started & Use code DRTYNA at checkout to receive 20% off today!  Topics Discussed: → What is Urolithin A and how does it help mitochondria? → How does Urolithin A support muscle and metabolism? → How are postbiotics, gut health, and GLP-1s connected? → What does Mitopure research show for immunity and brain health? → How can you use Timeline's Urolithin A daily? Sponsored By: →  Head to timeline.com/DRTYNA to get started & Use code DRTYNA at checkout to receive 20% off today!  On This Episode We Cover:  → 00:00:00 - Introduction  → 00:01:19 - Understanding Urolithin A  → 00:05:24 - Mitochondrial health  → 00:09:08 - Mitochondrial lifecycle  → 00:11:08 - Muscular growth & health  → 00:14:21 - Mitopure research  → 00:17:50 - Postbiotics & the gut microbiome  → 00:22:14 - GLP1s & the gut  → 00:26:31 - Gut rehabilitation  → 00:28:03 - Aging  → 00:31:26 - High protein diets & strength training  → 00:34:45 - Aging + muscle strength  → 00:39:34 - Mitopure, HRT, + stacking  → 00:46:21 - Skincare + topicals  → 00:49:25 - Immune health + inflammation → 00:52:37 - Summary  → 00:56:27 - Trying Timeline!  Show Links:  → Dr. Tyna's Strength Corner Further Listening:  → EP. 196 | The Answer Is The Gym | Quick + Dirty → Strength Training Playlist  Check Out Timeline →  Head to timeline.com/DRTYNA to get started & Use code DRTYNA at checkout to receive 20% off today!  Disclaimer: Information provided in this podcast is for informational purposes only. This information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional, or any information contained on or in any product. Do not use the information provided in this podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before taking any medication or nutritional, herbal or other supplement, or using any treatment for a health problem. Information provided in this blog/podcast and the use of any products or services related to this podcast by you does not create a doctor-patient relationship between you and Dr. Tyna Moore. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease.

You're living with MS, and maybe you're thinking about participating in an MS clinical trial. But how do they work? Are they safe? What's the difference between Phase 1, 2, and 3 trials? What are the real patient risks and benefits of participating in a clinical trial? In this special episode of RealTalk MS, we're getting answers to those questions and so much more from my guest, Dr. Aaron Boster. Dr. Boster is the founder of the Boster Center for Multiple Sclerosis in Columbus, Ohio, where he brings over 20 years of experience as an MS clinician. Dr. Boster has also  participated in more than 65 clinical trials.  This special episode of RealTalk MS has been made possible through a generous grant from Sanofi. Sanofi has two ongoing Phase 3 clinical trials in MS studying Frexalimab, an investigational second-generation anti-CD40 ligand monoclonal antibody. If you are interested in learning more about these clinical trials, please visit SanofiStudies.com SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/ct1 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! Privacy Policy

Sophie Sargent walked into the studio already owning the mic. A pandemic-era media rebel raised in New Hampshire, trained in Homeland Security (yep), and shaped by rejection, she's built a career out of DM'ing her way into rooms and then owning them. At 25, she's juggling chronic illness, chronic overachievement, and a generation that gets dismissed before it even speaks.We talk Lyme disease, Lyme denial, and the healthcare gaslighting that comes when you “look fine” but your body says otherwise. We dive into rejection as a career accelerant, mental health as content porn, and what it means to chase purpose without sacrificing identity. Sophie's a former morning radio host, country music interviewer, and Boston-based creator with a real voice—and she uses it.No fake podcast voice. No daddy-daughter moment. Just two loudmouths from different planets figuring out what it means to be seen, believed, and taken seriously in a system designed to do the opposite.Spoiler: She's smarter than I was at 25. And she'll probably be your boss someday.RELATED LINKSSophie on InstagramSophie on YouTubeSophie on LinkedInMedium article: “Redefining Rejection”See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What happens when you hand a mic to the most extroverted, uncensored Gen Z career coach in New York? You get Olivia Battinelli—adjunct professor, student advisor, mentor, speaker, and unfiltered truth-teller on everything from invisible illness to resume crimes.We talked about growing up Jewish-Italian in Westchester, surviving the Big Four's corporate Kool-Aid, and quitting a job after 7 months because the shower goals weren't working out. She runs NYU Steinhardt's internship program by day, roasts Takis and “rate my professor” trolls by night, and somehow makes room for maple syrup takes, career coaching, and a boyfriend named Dom who sounds like a supporting character from The Sopranos.She teaches kids how to talk to humans. She's allergic to BS. And she might be the most Alexis Rose-meets-Maeve Wiley-mashup ever dropped into your feed. Welcome to her first podcast interview. It's pure gold.RELATED LINKS:Olivia Battinelli on LinkedInOlivia's Liv It Up Coaching WebsiteOlivia on InstagramNYU Steinhardt Faculty PageFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.